Development of increasing functional HDL-C using antisense oligonucleotides as innovative therapy

点击翻译按钮获取中文摘要

The objective of this basic research is to analyze whether or not innovative antisense oligonucleotides targeted specific molecular gene would be candidate of increasing serum HDL-cholesterollevel through the ABCA1/apoA-I pathway. We previously demonstrated that transcription factor AP-2 negatively regulates the ATP-binding cassette A1 (ABCA1) gene through its Ser-phosphorylation by protein kinase PKD which is a common modulator of the DNA binding activity of AP-2 through their phosphorylation for negative regulation of the ABCA in genes expression. The Antisense oligoniculeotide modified BNA is so innovative that have stronger effective compared to previous one.In this study, we demonstrated that the PKD specific targeted antisense could increase ABCA1 mRNA levels in liver in vitro and in vivo, which result in raising serum HDL-C level in vivo. To further develop this strategy, we need more experiments to figure out the value of efficacy and safety using oligonucleotides therapy